By Dr Anne Blackwood, chief executive, Health Tech Enterprise
In today’s medical technology landscape, Artificial Intelligence has become the catch-all solution to every problem, or so it seems.
While AI is undoubtedly adding value in MedTech, its dominance in investor conversations has created an uneven playing field.
Founders developing clinically meaningful but non-AI-driven solutions may feel they are overshadowed by the buzz around AI and the focus placed on it by investors.
For MedTech innovators who are focused on building products that truly improve patient outcomes, the challenge is to shift the emphasis from technology-first to outcome-first.
True innovation is about delivering a change in the current standard of care with real measurable impact on health and costs.
Of course, securing investment still relies on the fundamental strengths of your product – clear clinical evidence and a proven market need.
However, with so much noise in the market, the real challenge is identifying the investors who truly understand the value of what you’re building. The question is, how do you make that happen?
What do MedTech investors actually want?
A polished pitch is your foot in the door, but a solid business plan is what drives long-term success.
Investors are looking for market insight and operational discipline, but above all, they want a team with a proven track record of bringing compliant, profitable products to market.
What does that mean for innovators?
- Lead with the Problem, Not the Tech
Investment starts with solving real problems in a market with genuine room to scale. Instead of opening with “We use AI to…,” start with the clinical or operational gap your product fills.
Take time to bottom out:
- The unmet need and its impact on patients and clinicians
- The clear market opportunity and how your solution uniquely fills it
- Why your product is essential, differentiated, and commercially viable
When investors see a clear alignment between clinical relevance and market logic, the technology becomes an enabler, not just a headline.
- Build the Right Team
Investors back the people, not just the technology.
A strong team with a history of bringing medical products to market gives investors confidence that you can navigate every stage – from initial concept through to compliance and commercialisation.
Focus on showing that your team has the right mix of skills and regulatory awareness to build a sustainable advantage.
Trends fade, but lasting value comes from solving real unmet clinical needs.
- Evidence Outcomes that Count
In a market that’s saturated with hype, your credibility rests on hard evidence. You need to showcase data that proves efficacy, safety, and adoption – clinical trials and peer-reviewed studies always speak louder than buzzwords.
But don’t stop at the data. It’s important to also demonstrate the real-world impact of your technology, i.e., how it actually changes a patient’s life, reduces a clinician’s workload, or transforms care delivery.
Combining clinical data with these tangible outcomes is what truly drives investment.
- Flaunt Your Regulatory Wins
Regulatory achievements such as FDA clearance, CE marking, or ISO certification immediately elevate investor confidence.
They prove that you’ve done the hard work, secured legal market access, and are ready to scale without the challenge of regulatory roadblocks.
- Prioritise Simplicity and Implementation
Unlike complex AI systems that can be difficult to explain, simplicity is a competitive advantage.
You need to show that your product is intuitive and, more importantly, that it fits easily into a clinician’s existing workflow. Investors look for products that are easy to adopt – if there’s no friction to getting started, it’s much easier to scale.
Beyond the Buzzwords
Once the hype fades, all that matters are the outcomes.
Founders who can demonstrate real-world value, patient benefits, and disciplined execution – backed by real market need – will always find investment, with or without AI.
The future of Medtech isn’t just AI; it will continue to be built on great ideas and the exceptional teams that can bring them to life.
About Dr Anne Blackwood
Dr Anne Blackwood is a prominent leader in the UK’s health innovation ecosystem, currently serving as the Chief Executive of Health Tech Enterprise (HTE).
With over 20 years of experience in technology transfer and intellectual property management, she has dedicated her career to bridging the gap between clinical research, academia, and the commercial market.
Prior to leading HTE, Anne spent several years at Cambridge Enterprise, the technology transfer office for the University of Cambridge, where she honed her skills in IP management and spin-out formation.
She holds a PhD in Chemistry, providing her with a rigorous scientific foundation that informs her commercial decision-making. Beyond her role at HTE, she is an active voice in the medtech community, often contributing to regional innovation boards and national committees aimed at improving patient care
